998 related articles for article (PubMed ID: 33613512)
1. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
Front Immunol; 2020; 11():585214. PubMed ID: 33613512
[TBL] [Abstract][Full Text] [Related]
2. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
De Cicco P; Ercolano G; Ianaro A
Front Immunol; 2020; 11():1680. PubMed ID: 32849585
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of targeting MDSCs in tumor microenvironment.
Sui H; Dongye S; Liu X; Xu X; Wang L; Jin CQ; Yao M; Gong Z; Jiang D; Zhang K; Liu Y; Liu H; Jiang G; Su Y
Front Immunol; 2022; 13():990463. PubMed ID: 36131911
[TBL] [Abstract][Full Text] [Related]
4. Implications of MDSCs-targeting in lung cancer chemo-immunotherapeutics.
Adah D; Hussain M; Qin L; Qin L; Zhang J; Chen X
Pharmacol Res; 2016 Aug; 110():25-34. PubMed ID: 27157248
[TBL] [Abstract][Full Text] [Related]
5. Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression.
Alban TJ; Bayik D; Otvos B; Rabljenovic A; Leng L; Jia-Shiun L; Roversi G; Lauko A; Momin AA; Mohammadi AM; Peereboom DM; Ahluwalia MS; Matsuda K; Yun K; Bucala R; Vogelbaum MA; Lathia JD
Front Immunol; 2020; 11():1191. PubMed ID: 32625208
[TBL] [Abstract][Full Text] [Related]
6. Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor.
Li BH; Garstka MA; Li ZF
Mol Immunol; 2020 Jan; 117():201-215. PubMed ID: 31835202
[TBL] [Abstract][Full Text] [Related]
7. Targeting myeloid-derived suppressive cells in the tumor microenvironment to enhance the efficacy of cancer immunotherapy.
Huo S; Liu L; Li Q; Wang J
Discov Med; 2020; 30(161):119-128. PubMed ID: 33593480
[TBL] [Abstract][Full Text] [Related]
8. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.
Li K; Shi H; Zhang B; Ou X; Ma Q; Chen Y; Shu P; Li D; Wang Y
Signal Transduct Target Ther; 2021 Oct; 6(1):362. PubMed ID: 34620838
[TBL] [Abstract][Full Text] [Related]
9. Suppression of T cells by myeloid-derived suppressor cells in cancer.
Chen J; Ye Y; Liu P; Yu W; Wei F; Li H; Yu J
Hum Immunol; 2017 Feb; 78(2):113-119. PubMed ID: 27939507
[TBL] [Abstract][Full Text] [Related]
10. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer.
Song J; Lee J; Kim J; Jo S; Kim YJ; Baek JE; Kwon ES; Lee KP; Yang S; Kwon KS; Kim DU; Kang TH; Park YY; Chang S; Cho HJ; Kim SC; Koh SS; Kim S
Oncotarget; 2016 Aug; 7(32):51840-51853. PubMed ID: 27322081
[TBL] [Abstract][Full Text] [Related]
12. Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy.
Li X; Zhong J; Deng X; Guo X; Lu Y; Lin J; Huang X; Wang C
Front Immunol; 2021; 12():754196. PubMed ID: 35003065
[TBL] [Abstract][Full Text] [Related]
13. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
Kamran N; Chandran M; Lowenstein PR; Castro MG
Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
[TBL] [Abstract][Full Text] [Related]
14. MMP-9-cleaved osteopontin isoform mediates tumor immune escape by inducing expansion of myeloid-derived suppressor cells.
Shao L; Zhang B; Wang L; Wu L; Kan Q; Fan K
Biochem Biophys Res Commun; 2017 Dec; 493(4):1478-1484. PubMed ID: 28986261
[TBL] [Abstract][Full Text] [Related]
15. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives.
Ibáñez-Vea M; Zuazo M; Gato M; Arasanz H; Fernández-Hinojal G; Escors D; Kochan G
Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):113-123. PubMed ID: 29032490
[TBL] [Abstract][Full Text] [Related]
16. Polysaccharide Agaricus blazei Murill stimulates myeloid derived suppressor cell differentiation from M2 to M1 type, which mediates inhibition of tumour immune-evasion via the Toll-like receptor 2 pathway.
Liu Y; Zhang L; Zhu X; Wang Y; Liu W; Gong W
Immunology; 2015 Nov; 146(3):379-91. PubMed ID: 26194418
[TBL] [Abstract][Full Text] [Related]
17. Epithelial-mesenchymal transition: When tumor cells meet myeloid-derived suppressor cells.
Cai J; Cui Y; Yang J; Wang S
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188564. PubMed ID: 33974950
[TBL] [Abstract][Full Text] [Related]
18. Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond.
Zhao Y; Du J; Shen X
Front Immunol; 2023; 14():1157537. PubMed ID: 37006306
[TBL] [Abstract][Full Text] [Related]
19. Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment.
Zhou J; Shen Q; Lin H; Hu L; Li G; Zhang X
J Cancer Res Clin Oncol; 2019 Feb; 145(2):329-336. PubMed ID: 30426212
[TBL] [Abstract][Full Text] [Related]
20. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]